P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)
Loges, S., Heuser, M., Chromik, J., Sutamtewagul, G., Kapp‐Schwoerer, S., Crugnola, M., Di Renzo, N., Lemoli, R., Mattei, D., Ben‐Batalla, I., Waizenegger, J., Rieckmann, L.‐M., Janning, M., Imbusch, C. D., Beumer, N., Micklem, D., Gorcea‐Carson, C., Lawson, G., Nautiyal, J., Deharo, S., Fiedler, W., Alvarado‐Valero, Y., Gjertsen, B.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
S839 PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (MDS)
Navada, S.C., Garcia‐Manero, G., Atallah, E., Rajeh, M.N., Shammo, J.M., Griffiths, E.A., Khaled, S.K., Dakhil, S.R., Young, D.E., Odchimar‐Reissig, R., Demakos, E.P., Alvarado Valero, Y., Ohanian, M.N., Pemmaraju, N., John, R.B., Zbyszewski, P.S., Maniar, M., Petrone, M.E., Woodman, R.C., Fruchtman, S.M., Silverman, L.R.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article